Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
This article provides an overview of the current state of the problem of effective pharmacotherapy for overactive bladder (OAB). The review presents standard pharmacotherapy and a new stage in the treatment of OAB--innovative drug Mirabegron. International and domestic studies confirmed high and predominant in many respects efficacy of mirabegron and a good safety profile. Conducted at the Research Institute of Urology own research demonstrated no influence on the quality of the bladder emptying, which proves the urodynamics safety. Taking into account the efficacy of mirabegron for all OAB symptoms, proven in a Randomized Clinical Tials (RCT), mirabegron has big potential and is able to make a revolution in the pharmacotherapy of OAB.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!